Working… Menu
Trial record 6 of 6 for:    Targovax

A Phase 1/2 Study to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02963831
Recruitment Status : Active, not recruiting
First Posted : November 15, 2016
Last Update Posted : June 23, 2021
Cancer Research Institute, New York City
MedImmune LLC
Targovax ASA
Information provided by (Responsible Party):
Ludwig Institute for Cancer Research

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : December 2021
Estimated Study Completion Date : December 2022